Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based
COVID-19 vaccine program to improve immune response in the elderly.
o Phase 1/2 interim results showed an immune response comparable to patients
who recovered from COVID-19 in adults aged 18 to 49 years
o Insufficient response in older adults demonstrates the need to refine the
concentration of antigen in order to provide high-level immune response
across all age groups
o Companies plan a Phase 2b study with an improved antigen formulation
o With support from BARDA as part of Operation Warp Speed, study to start in
February 2021, including a proposed comparison with an authorized COVID-19
vaccine
o Product availability now expected in Q4 2021 pending successful completion
of the development plan
https://www.bloomberg.com/press-release ... ove-immune
A bit disappointing methinks. Watch out for a weak GSK on market opening perhaps? I do intend topping up my holdings of GSK in January though, maybe?
Ian.